PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27^th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.

PolyPid’s fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, will take place from 11:30 AM – 12:00 PM ET on Monday, September 8, 2025.

The PolyPid management team will participate in virtual and in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with PolyPid through their H.C. Wainwright representative or e-mail meetings@hcwco.com.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics,  PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid’s lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd. 
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
polypid@arxadvisory.com